Trials / Completed
CompletedNCT00733863
Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.
A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mild Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo | |
| BIOLOGICAL | CAD106 |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2010-02-01
- First posted
- 2008-08-13
- Last updated
- 2020-02-11
Locations
4 sites across 4 countries: France, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00733863. Inclusion in this directory is not an endorsement.